Case report demonstrates expanded phenotypic spectrum in SHQ1-related disorder, suggesting diagnostic value of WES reanalysis.
SHQ1-related neurodevelopmental disorder is a rare autosomal recessive condition linked to disrupted ribosome biogenesis, telomerase activity, and RNA modification. Among the few reported cases, typical clinical presentations consist of early-onset hypotonia, seizures, movement disorders, and progressive neurologic impairment. We present a male patient who, at 4 months, displayed global developmental delay, hypotonia, feeding difficulties, and impaired cervical motor control. He progressed to exhibit choreiform movements and oromotor hypotonia. Extensive metabolic and genetic workup was unrevealing; whole exome sequencing (WES) in 2022 was nondiagnostic, and supportive measures were continued. In 2024, WES reanalysis identified compound heterozygous variants in SHQ1, NM_018130.4:c.523G>T (p.Gly175Cys) and NM_018130.4:c.828_831del (p.Glu276fs*12), both now recognized as pathogenic. Brain MRI was normal, and cerebrospinal fluid neurotransmitter analysis revealed reduced homovanillic acid, suggesting dopaminergic pathways. This case expands the clinical spectrum of SHQ1-related disorder by illustrating a milder phenotype with functional developmental gains and emphasis on the diagnostic value of WES reanalysis.
No takes yet. Share an insight, caveat, or question.
Ly et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: